Spero Therapeutics, Inc. · NASDAQ:SPRO
Spero Therapeutics — Corporate Update (January 2023)
5 slides from Spero Therapeutics's corporate update, Jan 9, 2023
Slide 1: Spero Therapeutics: A Leader in Infectious and Rare Diseases
Spero Therapeutics, Inc. A Leader in Infectious and Rare Diseases SPR720: Potential Novel, First Line, Oral Therapy for NTM Infections Strong Balance Sheet Supported by World Class Partnerships for Tebipenem HBr, SPR206 NTM = non-tuberculous mycobacterial; MDR = multidrug resistant infections; Tebip
Slide 2: SPR720 Patient Focus: First line NTM-MAC
SPR720 Patient Focus: First line NTM-MAC 75% of NTM patients are treatment naïve or treatment inexperienced, and eligible for first line therapy Treatment Naïve Bronchial hygiene/clearance, exercise, education Treatment Inexperienced NTM Refractory Disease None approved; Generic antibiotic regimens:
Slide 3: Clinical Experience Supports Safety, Efficacy of Tebipenem
Clinical Experience Supports Safety, Efficacy of Tebipenem1 Tebipenem pivoxil evaluated in 24 trials enrolling over 2500 subjects Approved in Japan since 2009 Spero experience: Global cUTI Phase 3, enrolling 1372 subjects Meiji Seika experience 741 Adult subjects evaluated, across 17 efficacy and ph
Slide 4: SPR206 Next Steps: Prepare for Phase 2 Trial
SPR206 Next Steps: Prepare for Phase 2 Trial SAD/MAD Phase 1 Trial No evidence of nephrotoxicity at predicted therapeutic dose levels Bronchoalveolar Lavage Phase 1 Trial Well-tolerated and achieved lung exposures consistent with predicted therapeutic levels Preclinical Studies Support increased eff
Slide 5: Financial Overview
Financial Overview $ in 000’s Income Statement Three Months Ended Sep 30, 2022 (unaudited) Twelve Months Ended December 31, 2021 Total Revenue $2,006 $18,256 R&D Expense $7,360 $64,526 G&A Expense $6,632 $41,701 Loss from Operations $(11,834) $(87,971) Net Loss Attributable to Common Stockholders $(